<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00207805</url>
  </required_header>
  <id_info>
    <org_study_id>MM01</org_study_id>
    <nct_id>NCT00207805</nct_id>
  </id_info>
  <brief_title>The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (&lt;61 Years) With Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre National de Greffe de Moelle Osseuse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre National de Greffe de Moelle Osseuse</source>
  <brief_summary>
    <textblock>
      Autologous peripheral blood stem cell (PBSC) transplantation is now considered standard
      therapy in patients (&lt; 65 ans) with multiple myeloma. The Intergroupe Francophone du Myelome
      conducted a randomised trial of the treatment of multiple myeloma with high dose chemotherapy
      followed by either one or two successive autologous stem cell transplantation. The
      probabilities of event-free-survival and overall survival were doubled with a double
      transplant. The benefits were greatest among patients who had not had a very good partial
      response to the first transplant.

      The aim of this multicenter randomised trial in previously untreated patients with multiple
      myelome (stage II, III DS)is to assess the optimal timing of a second autologous stem-cell
      transplant.After a first-line therapy with thalidomide-dexamethasone followed by a PBSC
      collection, patients are randomly assigned to receive two autologous PBSC transplants (arm
      A)or one autologous PBSC transplant followed by a consolidation therapy with
      thalidomide-dexamethasone (arm B). Patients included in the arm B will receive a second
      transplant in case of disease progression on consolidation therapy, or in case of relapse in
      responders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (from randomistion) of the 2 groups at 5 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free-survival</measure>
  </secondary_outcome>
  <enrollment>202</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous PBSC transplant</intervention_name>
    <description>optimal timining of a second autologous transplant</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients less than 61 years of age

          -  Durie Salmon stage II or III

          -  written and informed consent

        Exclusion Criteria:

          -  Prior treatment for myeloma

          -  ECOG performance score of 4

          -  Positive HIV test

          -  Chronic respiratory disease (DLco &lt; 60%)

          -  Systolic ejection fraction &lt; 50%

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>abderrahman abdelkefi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre National de Greffe de Moelle Osseuse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>abderrahman abdelkefi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre National de Greffe de Moelle Osseuse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre National de Greffe de Moelle Osseuse</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <results_reference>
    <citation>Abdelkefi A, Torjman L, Ben Romdhane N, Ladeb S, El Omri H, Ben Othman T, Elloumi M, Bellaj H, Lakhal A, Jeddi R, Aissaouï L, Saad A, Hsaïri M, Boukef K, Dellagi K, Ben Abdeladhim A. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (&lt;61 years) with symptomatic multiple myeloma. Bone Marrow Transplant. 2005 Aug;36(3):193-8. Retraction in: Bone Marrow Transplant. 2009 Jun;43(11):893.</citation>
    <PMID>15968290</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>January 26, 2009</last_update_submitted>
  <last_update_submitted_qc>January 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

